Emyria Ltd · ASX:EMD
Emyria — Corporate Update (September 2023)
43 slides from Emyria's corporate update, Sep 6, 2023
Slide 1: Strategic Update & Rights Issue Launch
Creating tomorrow’s therapies from today’s patient stories (ASX:EMD) Strategic Update & Rights Issue Launch September 2023 | mwinlo@emyria.com
Slide 2: Our Mission
OUR MISSION Set a new standard for global mental health care by blending compassionate care, data insights and pioneering therapies.
Slide 3: 7 Investment Highlights for Emyria
7 INVESTMENT HIGHLIGHTS for EMYRIA (ASX : EMD) Australia is At the forefront Novel MDMA Unparalleled Clinics CBD “Side bets” Experienced leading the of psychedelic products access to delivering management charge globally assisted patient data revenue team in new treatment treatments for mental healt
Slide 4: The Global Mental Health Challenge | Seeking New Solutions
THE GLOBAL MENTAL HEALTH CHALLENGE | SEEKING NEW SOLUTIONS Rising Demand, The Promise of The Challenge of Inadequate Solutions Psychedelic-Assisted Psychedelic-Assisted Therapy Therapy $225 Billion US Spending (2019) 1 Psychedelic-assisted therapy is showing Safe delivery of psychedelic-assisted the
Slide 5: Australia's Frontier | Embracing Drug-Assisted Therapies
AUSTRALIA'S FRONTIER | EMBRACING DRUG-ASSISTED THERAPIES Leading the Global Not Just Drugs, Emyria’s Model is Charge But Holistic Care Well Positioned TGA's recent rescheduling 1 of MDMA-assisted therapy The future of mental healthcare will (MDMA-AT) for PTSD & psilocybin-assisted therapy intertwine
Slide 6: Emyria's Unique Business Model
EMYRIA’S UNIQUE BUSINESS MODEL | MERGING CARE DELIVERY & DRUG DEVELOPMENT care DELIVERY real-world DATA drug DEVELOPMENT ● National clinics & telehealth ● We track clinical outcomes ● MDMA-inspired medicines ● 30 clinicians & specialists ● Palantir Foundry as core data ● Ultra-Pure CBD medicines ● 1
Slide 7: Creating & Capturing Value | Our Strategy for Growth & Impact
CREATING & CAPTURING VALUE | OUR STRATEGY FOR GROWTH & IMPACT (1) Solidify Multiple Potential (2) Sustainable National Revenue Streams Via: and Global Growth Via: DIRECT PATIENT TREATMENTS: TECH-DRIVEN OPTIMISATION Provides potential to generate steady Leveraging technology ensures efficient revenues
Slide 8: Our Current Focus | Complex Mental Health
OUR CURRENT FOCUS | COMPLEX MENTAL HEALTH 35% of Australian adults experienced at least 1 mental health challenge in the last 12 months 1 Amidst Australia's mental health landscape, we're prioritising unmet needs in anxiety disorders with PTSD proprietary dose forms of Anxiety disorders (6%) cannabi
Slide 9: What Is Post-Traumatic Stress Disorder (PTSD)?
A chronic, debilitating mental health disorder WHAT IS POST-TRAUMATIC STRESS DISORDER (PTSD)? 1 that can occur following a traumatic event Symptoms Current Market for Treatments MDMA-AT 3 Total Addressable Market (TAM) Re-experiencing: In any 12 month period, PTSD affects 6% of Intrusive memories, fl
Slide 10: MDMA-Assisted Therapy Showing Remarkable Promise for PTSD
MDMA-ASSISTED THERAPY (MDMA-AT) SHOWING REMARKABLE PROMISE FOR PTSD 1 Improves symptoms Improves function Durable benefits “ The majority of participants reported lasting benefits at Long Term Follow-Up, and over half reported benefits continued to grow, suggesting participants were able to successfull
Slide 11: How Does MDMA-AT Work?
HOW DOES MDMA-AT WORK? Role in Therapy MDMA Clinical Effects of MDMA MDMA is thought to assist patients access traumatic memories without overwhelming MDMA is an “entactogen” - drugs distress. that produce feelings of emotional communion, oneness, relatedness, The improved feelings of trust and well
Slide 12: Emyria's MDMA-AT Model
EMYRIA’S MDMA-AT MODEL Ethics-Approved Anticipated Cost-Effective Who Might Pay For Care Model 1 Compared to Standard Care2 MDMA-AT? Fit-for-purpose clinical space Health insurers and government We will approach payers to offer our support in Trained multidisciplinary team the evaluation cost-effect
Slide 13: Our Team's Advantages
OUR TEAM’S ADVANTAGES | LEADERS IN CARE, DATA and DRUG DEVELOPMENT Innovative Care Data, Research & Global Drug Delivery Technology Development Success Our team has experience across clinical With experience at from Silicon Valley Our team has experience across the vast care, consulting, and academi
Slide 14: Our Board / Clinical & Scientific Leadership
OUR BOARD CHAIRMAN NE-DIRECTOR E-DIRECTOR MANAGING DIRECTOR NE-DIRECTOR MEDICAL DIRECTOR Dr Stewart Washer Prof Sir John Tooke Dr Karen Smith Dr Michael Winlo Dr Mohit Kaushal C/Prof Alistair Vickery PhD (Microbiology) FRCP, FMedSci MD, PhD, MBA, LLM MBBS(Hons), MBA Technology enabled MBBS, FRACGP,
Slide 15: Proven Momentum | Traction to Date
PROVEN MOMENTUM | TRACTION TO DATE Key Milestones Robust Patient Strategic Growth Achieved Outcomes Initiatives MDMA-assisted therapy (MDMA-AT) 14,000 Ethics-approved protocol, training Patients treated through our clinical completed & drug supply secured 1 Acquisition of Australia’s leading, servic
Slide 16: Our Roadmap
OUR ROADMAP # PROGRAM MILESTONE 1 MILESTONE 2 MILESTONE 3 OTHERS Emyria psychiatrists Complete patient Complete Phase Begin treatment on recruitment for 1 Deliver MDMA-AT first patient (MDMA) obtain Authorised Phase 2b trial 2b trial for Prescriber status MDMA (MDMA) Animal study results Animal study
Slide 17: Our Corporate Structure
OUR CORPORATE STRUCTURE KEY METRICS VALUE Market Capitalisation ~A$31M Tenmile Last reported cash A$2.73M (at 30 Jun 2023) + $2m Placement (Sep) 7.8% + $3.1m Rights Issue (Oct) Other Holdings Directors 27% Top 50 67.2% Emyria 2023 17
Slide 18: Entitlement Offer to Raise $3.1m
ENTITLEMENT OFFER TO RAISE $3.1m Emyria 2023 18
Slide 19: Entitlement Offer | Overview
ENTITLEMENT OFFER | OVERVIEW Emyria (EMD) is launching a Entitlement Offer (“Offer”) to provide existing shareholders the opportunity to invest in advancing the next phases of our highly promising clinical programs. Offer is expected to raise For every 7.5 shares held by the Record Date, $3.1m (befo
Slide 20: Entitlement Offer | Use of Funds
ENTITLEMENT OFFER | USE OF FUNDS $3.1m PROPOSED EXPENDITURE CARE DELIVERY Finalise Pax Acquisition $500,000 Authorised prescriber launch $375,000 Service expansion (ketamine) $775,000 DRUG DEVELOPMENT CBD drug optimisation $350,000 MDMA-analogues 1 lead series to animal studies $793,300 DATA $250,00
Slide 21: Entitlement Offer | Indicative Timetable
ENTITLEMENT OFFER | INDICATIVE TIMETABLE Event Date (2023) Lodgement of Entitlement Offer Prospectus with ASIC 5 September Announcement of Entitlement Offer Prospectus and investor presentation on ASX 6 September Entitlement Offer “Ex” date 12 September Expected date for quotation of new shares issu
Slide 22: Entitlement Offer (Rights Issue) | Website Explaining the Offer
ENTITLEMENT OFFER (RIGHTS ISSUE) | WEBSITE EXPLAINING THE OFFER OFFER.EMYRIA.COM Emyria 2023 22
Slide 23: Entitlement Offer | Disclaimer
ENTITLEMENT OFFER | DISCLAIMER In accordance with section 734(6) of the Corporations Act, the Company notes that: ● the Entitlement Offer will be undertaken pursuant to a disclosure document issued by the Company in accordance with section 713 of the Corporations Act (the Prospectus); ● the Prospect
Slide 24: Contact Information
CONTACT INFORMATION Michael Winlo mwinlo@emyria.com Investors investors@emyria.com Media media@emyria.com General info@emyria.com INVESTOR HUB: https://investorhub.emyria.com/
Slide 25: Appendix
APPENDIX: Emyria 2023 25
Slide 26: Disclaimer to Presentation
DISCLAIMER to presentation This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any
Slide 27: Emyria Clinics | Our Expanding Mental Health Footprint
EMYRIA CLINICS | OUR EXPANDING MENTAL HEALTH FOOTPRINT We offer a suite of solutions & ongoing support, not just a single service A data-centric clinic working with newly rescheduled treatments like THC Australia’s leading, multidisciplinary treatment centre for psychological trauma & CBD. We monito
Slide 28: Emyria Clinics | A Personalised Path to Mental Wellness
EMYRIA CLINICS | A PERSONALISED PATH TO MENTAL WELLNESS We offer wraparound care before, during and after treatment ACTIVE ASSESSMENT, DATA COLLECTION & REVIEW Neuropsychiatric disorders share an overlapping imprint of poor body health 1 which is why Emyria’s care models prioritise both physical and
Slide 29: Emyria Clinics | Multidisciplinary Model
EMYRIA CLINICS | MULTIDISCIPLINARY MODEL SERVICE MODEL KEY STRENGTHS KEY LIMITATIONS EMYRIA ADVANTAGES Accessible, Limited support; ✓ Provides specialised care with GP Clinics generalised care not specialised robust support High-level, Often do not address physical ✓ Offers multidisciplinary care co
Slide 30: MDMA-AT Effects on Alcohol and Substance Disorder & Suicidality
MDMA-AT EFFECTS On Alcohol and Substance Disorder (“ASUD”) & Suicidality MDMA-AT may lead to subclinical MDMA-AT does not increase risk of illicit MDMA-AT may reduce the risk of suicidality improvements in alcohol use drug use Compared to Placebo+therapy, Changes in DUDIT scores were not Serious sui
Slide 31: Epidemiology of Post-Traumatic Stress Disorder
EPIDEMIOLOGY OF POST-TRAUMATIC STRESS DISORDER 1 Adults % with Adults % with Adult PTSD % with Adult PTSD Cost TAM aged > 18 current with chronic cases that disqualifying cases eligible to Treat (millions) PTSD PTSD and are chronic condition for MDMA-AT severe or severe USA 250.5 3.60% 9,018,000 50%
Slide 32: Medicine-Assisted Therapies Progress
In Active Completed Development MEDICINE-ASSISTED THERAPIES MDMA-ASSISTED THERAPIES Ethics-Approved Drug Supply First Patient First Patient Trained Team Care Model Secured Consented Treated KETAMINE-ASSISTED THERAPIES 1 Trained Team Ethics-Approved Drug Supply First Patient First Patient Care Model
Slide 33: What's Next? Ketamine-AT
WHAT’S NEXT? Ketamine-AT Clinical Effects Role in Therapy KETAMINE Clinical effects of ketamine can vary Ketamine induces a brief dissociative state, allowing patients to view memories or depending on the dose, route of thoughts differently. administration, and individual patient factors. In general
Slide 34: What's Next? Psilocybin-AT
WHAT’S NEXT? Psilocybin-AT Clinical Effects Role in Therapy PSILOCYBIN The clinical effects of psilocybin can vary Psilocybin is understood to amplify emotional depending on the dose, route of understanding and connection, making it easier administration, and individual patient for people to revisit
Slide 35: Emyria Drug Development | MDMA-Analogues
EMYRIA DRUG DEVELOPMENT | MDMA-ANALOGUES One of the world’s largest libraries of MDMA analogues developed with Dopamine associated with feelings of pleasure and satisfaction Screened for selective Proprietary modulation of major Serotonin analogue library neurotransmitters thought to contribute to f
Slide 36: MX1 | Potentially Shorter-Acting MDMA-Like Medicines
MX1 | multiple | POTENTIALLY SHORTER-ACTING MDMA-LIKE MEDICINES Target Indication & Key Preclinical Results Next Steps Market MDMA looks very promising as an Metabolic studies performed to-date demonstrate adjunct with psychotherapy for PTSD. Emyria’s compound library contains novel MDMA ● analogues
Slide 37: MX2 | UWA-101 | Potential Treatment L-DOPA Induced Dyskinesia
MX2 | UWA-101 | POTENTIAL TREATMENT L-DOPA INDUCED DYSKINESIA (LID) Target Indication & Key Preclinical Result Next Steps Market In a gold-standard primate model of Parkinson’s Disease, Parkinson’s Disease (PD) is the world’s MDMA-analogue UWA-101, had a significant effect on fastest growing neurolog
Slide 38: Emyria Drug Development | Ultra-Pure CBD
EMYRIA DRUG DEVELOPMENT | ULTRA-PURE CBD We’ve developed multiple dose forms targeting registration as capsule medicines EMD-RX5 EMD-RX7 EMD-RX9 EMD-MX1 EMD-MX1 EMD-MX1 An Ultra-Pure CBD capsule for High bioavailability Ultra-Pure CBD High potency, high bioavailability over-the-counter treatment of
Slide 39: EMD-RX5 Product Development Update
EMD-RX5 PRODUCT DEVELOPMENT UPDATE Update Data Next steps During routine quality assessments a difference in A new manufacturing method is being dissolution rates between two batches of developed, using an updated manufacturing EMD-RX5 was identified. For clarity, "dissolution process and a new batch
Slide 40: Emyria Data | Palantir Foundry - Advanced Data Integration & Analysis
EMYRIA DATA | Palantir Foundry - ADVANCED DATA INTEGRATION & ANALYSIS Emyria 2023 40
Slide 41: Emyria Data | Emerald Care Model Improves Quality of Life Symptoms
EMYRIA DATA | EMERALD CARE MODEL IMPROVES QUALITY OF LIFE SYMPTOMS We are experienced in tracking clinical outcomes & personalising care % of patients with “moderate” to “severe” ANXIETY, DEPRESSION, STRESS CLINICAL IMPACT EXAMPLE: Our Cannabinoid-Based Care Model Can Improve Symptoms Of Psychologic
Slide 42: Emyria Data | Emerald Care Model Reduces Opioid Use
EMYRIA DATA | EMERALD CARE MODEL REDUCES OPIOID USE We are experienced in tracking clinical outcomes & personalising care CLINICAL IMPACT EXAMPLE: OUR CANNABINOID-BASED CARE MODEL CAN REDUCE OPIOID USE 1 SOURCES: Emyria 2023 42 1. See ASX release 18 Jun 2021
Slide 43: Emyria Intellectual Property
EMYRIA INTELLECTUAL PROPERTY TITLE OFFICIAL NO. STATUS MDMA Analogues 2021903836 PCT filed (search report due ‘23) Cannabidiol Dosing Regime 2021902001 PCT filed Cannabinoid Dosage Form 2022900479 PCT filed Use of Cannabidiol for the Treatment of Psychological Distress 2020904152 PCT filed Use Of Cannab